HUTCHMED (China) Limited Sponsored ADR

HCM Healthcare Drug Manufacturers Specialty & Generic

HUTCHMED (China) Limited Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $548.5 million, down 13.0% from fiscal 2024.

14.27 0.35 +2.51%
Market cap
$2.5B
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
4/9
Altman Z
3.53
Beneish M
−1.20
Dividend safety
n/a

HUTCHMED (China) Limited Sponsored ADR (HCM) P/S ratio

Alert me on P/S ratio

HUTCHMED (China) Limited Sponsored ADR has no meaningful P/S ratio: its trailing twelve-month sales is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.

P/S ratio, daily

Embed this chart

Annual newest first

Period P/S ratio Change
FY2025 0.0× —
FY2024 0.0× —
FY2023 0.0× —
FY2022 0.0× —
FY2021 0.0× —
FY2020 0.0× —
FY2019 0.0× —
FY2018 0.0× —
FY2017 0.0× —
FY2016 0.0× —

Quarterly newest first

Period P/S ratio Change
Jun 2023 1.0× (59.57%)
Dec 2022 2.5× 6.71%
Jun 2022 2.3× 18.66%
Jun 2021 2.0× 29.15%
10 more quarters

Against its own ten years

Low 0.0× High 0.0×
Ten-year median 0.0×
Current reading's percentile 100

P/S ratio against peers

Company P/S ratio
HCM HUTCHMED (China) Limited Sponsored ADR n/m
PRGO Perrigo Company plc compare 0.5×
ANIP ANI Pharmaceuticals, Inc. compare 1.4×
PBH Prestige Consumer Healthcare Inc. compare 1.8×
TRLV Trulieve Cannabis Corp. compare 2.0×
BCRX BioCryst Pharmaceuticals, Inc. compare 2.0×
ALVO Alvotech compare 4.6×
XERS Xeris Biopharma Holdings, Inc. compare 6.4×
RGC Regencell Bioscience Holdings Limited compare —
Drug Manufacturers Specialty & Generic industry median 2.1×
Healthcare sector median 3.5×
Market median 1.9×

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

More on HCM